A phase I/II b (randomized controlled) study of atezolizumab combined to BEGEV regimen as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate to autologous stem–cell transplantation. - FIL_A-BEGEV

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2021
This article has no abstract
Epistemonikos ID: 9eab88e21119477fff2a41e535e9170c25d07905
First added on: Apr 17, 2025